U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932081) titled 'Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry' on March 02.
Brief Summary: This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Study Start Date: Jan. 01, 2023
Study Type: OBSERVATIONAL
Condition:
Adult Congenital Heart Disease
Congenital Heart Disease
Systemic Right Ventricle
Transposition of the Great Arteries
Cong...